Allarity Therapeutics

📢 Allarity Therapeutics Strengthens Leadership Team to Drive Clinical Development of Stenoparib We are excited to announce key leadership appointments that will accelerate the development of our lead program, stenoparib, a promising dual-targeted PARP and Tankyrase inhibitor for advanced ovarian cancer. 🧬 Jeremy Graff, PhD – Former Eli Lilly and Company Research Fellow, appointed as President and Chief Development Officer. With decades of experience in oncology drug development, Dr. Graff will lead our clinical development. Jose Iglesias, MD – Former Eli Lilly and Celgene veteran, joins as Consultant Chief Medical Officer. Dr. Iglesias’ global experience in oncology will be critical in advancing stenoparib toward regulatory approval. Jesper Høiland – Former President of Novo Nordisk’s U.S. Operations, appointed as Strategic Advisor. Mr. Høiland brings his global pharmaceutical leadership to guide our strategic initiatives and commercialization efforts. 🗨️ Thomas Jensen, CEO of Allarity Therapeutics, commented on the appointments: “We are thrilled to welcome Jeremy Graff, Jose Iglesias, and Jesper Høiland to their new roles within Allarity. Each brings a wealth of experience and proven leadership in their respective fields, which will be instrumental as we continue to advance stenoparib’s development. Dr. Graff’s deep expertise in oncology drug development, combined with his track record in advancing targeted cancer therapies, will be invaluable. Dr. Iglesias’ extensive clinical oncology background will strengthen our strategy and drive stenoparib toward regulatory approval. Jesper Høiland’s insights from global pharmaceutical leadership, particularly in financing and commercial strategy, will help us optimize the commercial potential of the DRP and stenoparib. I am confident their combined expertise will enhance our efforts to bring innovative cancer therapies to patients in need.” 🔗 Read the full press release here: https://bit.ly/3BvndFJ #CancerResearch #Oncology #Leadership #Biotech #Pharmaceuticals #CancerTreatment #Stenoparib #PARPInhibitor #AllarityTherapeutics

📢 Exciting News from Allarity Therapeutics We are pleased to announce that two patients in our Phase 2 trial for stenoparib in advanced ovarian cancer have now exceeded one year of continuous treatment, showing durable clinical benefit. This achievement highlights the potential of stenoparib, a dual PARP/Tankyrase inhibitor, to provide extended therapeutic value for heavily pre-treated ovarian cancer patients. Our CEO, Thomas Jensen, stated in our just-released press release: "For heavily pre-treated ovarian cancer patients, extending life by 52 weeks is particularly noteworthy.  Stenoparib’s unique mechanism of action, as both a PARP and Tankyrase inhibitor, sets it apart from other treatments." Our clinical research continues, and we remain committed to advancing stenoparib toward regulatory approval. 💡 Learn more about our progress in the full press release below ⬇️ #AllarityTherapeutics #OvarianCancer #Stenoparib #ClinicalResearch #CancerTreatment

📢 Allarity Therapeutics Welcomes New CFO, Alex Epshinsky We are excited to announce the appointment of Alex Epshinsky, CPA, as our new Chief Financial Officer (CFO). Alex brings nearly a decade of financial leadership experience from several biotech companies, including roles at Avenue Therapeutics, Aruvant, and Turnstone Biologics. His expertise in financial management will be instrumental as we continue advancing our lead program, stenoparib, for the treatment of advanced recurrent ovarian cancer. A warm welcome to Alex! 👏 #AllarityTherapeutics #NewHire #Leadership #CFO #Biotech #Oncology #CancerTreatment

We are excited to share our recent business update and highlight two key achievements: 🔹 Current Cash Balance: Allarity Therapeutics is thrilled to report a robust cash balance of $20 million, providing a runway extending into 2026 at our current burn rate. This financial stability enables us to continue our critical work without interruption. 🔹 Pausing the ATM: To safeguard our financial health and minimize shareholder dilution, we are pausing our At-The-Market (ATM) offering program for the foreseeable future. Our new management has made significant strides in enhancing our financial position and streamlining operations. We've also concentrated all our efforts on advancing stenoparib, our promising dual PARP and Tankyrase inhibitor, which continues to show promising results in Phase 2 trials. Click below to read the full press release ⬇️ #AllarityTherapeutics #BusinessUpdate #FinancialProgress #CancerResearch #Stenoparib

We just announced that multiple advanced ovarian cancer patients have now exceeded 30 weeks on treatment with our dual PARP/Tankyrase inhibitor, stenoparib, demonstrating significant tumor shrinkage and long-term disease stability. These clinical trial findings underscore the potential of stenoparib to provide a new treatment option for patients with limited alternatives. We are committed to advancing stenoparib in further clinical trials and towards regulatory approval. Press release: https://bit.ly/3VX2Glm Image: molecular model of stenoparib #CancerResearch #OvarianCancer #ClinicalTrials

📢 Q1 Report Updates from Allarity Therapeutics! We are pleased to announce our Q1 financial results and key operational highlights, which showcase improved financial stability and progress toward NASDAQ compliance. 🔹 On track for NASDAQ compliance 🔹 Enhanced equity of $15M and a strong cash balance of $14M 🔹 Simplified capital structure with significant reductions in debt Read the full press release for more details: https://bit.ly/4dIEk5M #Pharma #Biotech #FinancialResults #Q1

🎉 Exciting News 🎉 We are pleased to share that our Phase 2 clinical trial of stenoparib for advanced ovarian cancer has concluded early due to clear clinical benefits observed, including tumor shrinkage and long-term disease stability in heavily pre-treated patients. This marks a significant milestone for stenoparib, showing promising proof of concept as a monotherapy. Thanks to our unique DRP® companion diagnostic, we were able to pre-screen patients to ensure the highest likelihood of benefit. This success enables us to accelerate the development of a follow-on trial with FDA regulatory intent. Read the full press release: https://bit.ly/3Qr8D6O #OvarianCancer #ClinicalTrials #PersonalizedMedicine #HealthcareInnovation #Biotech #Pharma Image: Molecular model of stenoparib.

🔬 Important Update on Allarity Therapeutics' Strategic Focus We have refined our focus to concentrate exclusively on the development of stenoparib for advanced recurrent ovarian cancer. This decision comes after careful analysis and the encouraging data observed in our ongoing Phase 2 monotherapy trial of stenoparib. Our aim is to expedite the process toward regulatory approval, dedicating our resources to this critical endeavor.   Key Points:   The ongoing Phase 2 trial of stenoparib shows significant clinical benefit, with patients experiencing extended treatment durations: - Clinical benefit has now exceeded 20 weeks for each of the five patients originally mentioned in the December release. - The Complete Responder, referenced in the December release, has confirmed continued response through multiple additional scans and remains on therapy. We are committed to advancing stenoparib as swiftly and safely as possible, believing in its potential to make a meaningful difference for patients. #AllarityTherapeutics #OvarianCancer #ClinicalTrials #Oncology #Pharmaceuticals Image: a molecular model of stenoparib

🔬 We are excited to share that our CEO, Thomas Jensen, has been invited to present at Oxford Global's Biomarkers 2024 in London! He will provide insights into our development of the Drug Response Predictor (DRP®) platform and its potential impact on personalized cancer treatment, focusing on our ongoing trial with #stenoparib for ovarian cancer.   More info: https://bit.ly/3OUUldJ #Biomarkers2024 #CancerResearch #CDx #OvarianCancer

At Allarity Therapeutics, we are excited to share some important news regarding our leadership team and strategic advisory. Thomas Jensen, a co-founder and a respected member of our Board of Directors, has taken on the role of Interim Chief Executive Officer. With nearly two decades of dedication and an in-depth understanding of our DRP® companion diagnostic technology, Thomas is exceptionally well-equipped to lead us through this transition. In addition, we are delighted to welcome Jeremy Graff, PhD, as an Executive Advisor. With over 25 years of experience in the biotech and pharma industry, especially in the development of targeted cancer therapies, Dr. Graff's expertise will be invaluable as we continue to advance our research and development programs. Full press release: #Leadership #ExecutiveAppointment #Oncology #PersonalizedMedicine #DRP